Oddo BHF Asset Management Sas Takes $8.91 Million Position in Stryker Co. (NYSE:SYK)

Oddo BHF Asset Management Sas acquired a new stake in Stryker Co. (NYSE:SYK - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,656 shares of the medical technology company's stock, valued at approximately $8,907,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Dunhill Financial LLC increased its stake in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after acquiring an additional 37 shares during the period. Centennial Bank AR grew its holdings in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock worth $32,000 after acquiring an additional 48 shares during the period. Darwin Wealth Management LLC acquired a new stake in Stryker in the third quarter valued at $36,000. HBW Advisory Services LLC purchased a new stake in shares of Stryker during the 3rd quarter worth $42,000. Finally, Hara Capital LLC acquired a new position in shares of Stryker during the 3rd quarter worth $42,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on SYK. Citigroup upped their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a "buy" rating in a research report on Wednesday. Canaccord Genuity Group upped their target price on Stryker from $360.00 to $400.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. UBS Group lifted their price target on Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 30th. Wolfe Research assumed coverage on shares of Stryker in a report on Tuesday, September 10th. They set an "outperform" rating and a $405.00 target price for the company. Finally, Robert W. Baird upped their price target on shares of Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and an average target price of $404.35.

Stryker Trading Down 0.1 %

SYK traded down $0.31 on Friday, reaching $374.75. 755,824 shares of the company's stock were exchanged, compared to its average volume of 1,257,977. Stryker Co. has a twelve month low of $285.79 and a twelve month high of $398.20. The company's 50 day moving average is $372.88 and its 200-day moving average is $354.65. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The company has a market cap of $142.86 billion, a price-to-earnings ratio of 40.19, a PEG ratio of 2.84 and a beta of 0.94.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.46 EPS. Equities analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.90%. This is a positive change from Stryker's previous quarterly dividend of $0.80. Stryker's dividend payout ratio (DPR) is currently 34.30%.

Insider Activity

In related news, VP M Kathryn Fink sold 7,347 shares of the company's stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company's stock, valued at $3,685,213.16. This represents a 42.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kevin Lobo sold 57,313 shares of the firm's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.